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Abstract: The use of nanoparticles as tumor-targeting agents is steadily increasing, and the influence
of nanoparticle characteristics such as size and stealthiness have been established for a large number of
nanocarrier systems. However, not much is known about the impact of tumor presence on nanocarrier
circulation times. This paper reports on the influence of tumor presence on the in vivo circulation
time and biodistribution of polybutadiene-polyethylene oxide (PBd-PEO) polymersomes. For this
purpose, polymersomes were loaded with the gamma-emitter 111In and administered intravenously,
followed by timed ex vivo biodistribution. A large reduction in circulation time was observed for
tumor-bearing mice, with a circulation half-life of merely 5 min (R2 = 0.98) vs 117 min (R2 = 0.95) in
healthy mice. To determine whether the rapid polymersome clearance observed in tumor-bearing
mice was mediated by macrophages, chlodronate liposomes were administered to both healthy
and tumor-bearing mice prior to the intravenous injection of radiolabeled polymersomes to deplete
their macrophages. Pretreatment with chlodronate liposomes depleted macrophages in the spleen
and liver and restored the circulation time of the polymersomes with no significant difference in
circulation time between healthy mice and tumor-bearing mice pretreated with clodronate liposomes
(15.2 ± 1.2% ID/g and 13.6 ± 2.7% ID/g, respectively, at 4 h p.i. with p = 0.3). This indicates that
activation of macrophages due to tumor presence indeed affected polymersome clearance rate. Thus,
next to particle design, the presence of a tumor can also greatly impact circulation times and should
be taken into account when designing studies to evaluate the distribution of polymersomes.
Keywords: radiolabeled polymersomes; clodronate liposomes; circulation time; healthy and
tumor-bearing mice; macrophages
1. Introduction
The use of nanoparticles in medicine is increasingly gaining attention, mainly in cancer-related
therapies, but also extending to HIV, asthma, and other infections [1]. While only a few nanoparticle-based
drugs have made the translation to the clinic [2], they show great promise in, for example, reducing
toxicity [3,4]. They provide a versatile platform for theranostic approaches, allowing for easy surface
modification and/or encapsulation of drugs and contrast agents. There are a number of well-established
factors which have to be taken into account when designing nanocarrier studies resulting in the
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desired tumor accumulation of the nanocarrier in question. Many nanocarrier designs rely on passive
tumor targeting, making use of the leaky tumor vasculature combined with poor lymphatic drainage
(the enhanced permeability and retention (EPR) effect). The accumulation of nanoparticles through
passive targeting therefore depends on the physiological properties of the tumor [5], as the EPR
effect may differ between tumor models [6]. Tumor models which exhibit high EPR effect include
CFPAC-1 [7], MDA-MB-231 [8,9], and 4T1 [10,11]. However, for sufficient accumulation at the tumor site
through passive targeting, it is also essential to design long-circulating nanocarriers, as one of the main
challenges for targeted drug delivery is their fast uptake by the mononuclear phagocyte system (MPS).
Factors involved with the uptake of nanoparticles by the MPS are degree of PEGylation (polyethylene
glycol), size, and surface charge [12,13]. PEGylation has been shown to minimize opsonization for a
number of nanoparticles, including liposomes and polymer-based nanoparticles [14], resulting in a
1–2 order of magnitude increase in circulation time [15–17]. The optimal vesicle size can depend on
the nanocarrier type; for example, whereas the optimal liposome diameter appears to be between 50
and 200 nm [18,19], polymersomes have a much stricter size constraint, with optimal circulation times
around 90 nm while 120 nm vesicles are quickly cleared from the blood [20]. While many studies have
focused on the influence of nanoparticle properties as well as tumor models, the influence of tumor
presence on nanoparticle circulation time has barely been researched. This is of utmost importance in
selecting preclinical models used for investigating the circulation time and tumor-targeting properties
as these characteristics may strongly be affected by presence of tumor cells [21,22].
Previously, we have studied the use of polymersomes for the application of radionuclide therapy.
Polymersomes [21,23–25] are versatile nanocarriers which allow easy modification of physicochemical
properties creating a large number of possible applications [26]. They are often compared to liposomes,
which are composed of phospholipids instead of block copolymers, due to their similar amphiphilic
nature [27]. Their circulation half-life has in fact been found to be similar to that of stealth liposomes [28].
However, their ability to efficiently encapsulate and retain radionuclides in their aqueous compartment,
including their potential application in alpha radionuclide therapy where they have proven to retain
daughter nuclides better than their lipid counterparts [23,24], makes them an interesting nanocarrier
model for targeted alpha therapy. Many in vivo studies with polymersomes have been performed in
BALB/c or NCr nude mice, which have a severely comprised immune system. However, in an earlier
study, we have observed reduced polymersome circulation time upon the presence of a tumor [21].
Despite the fact that these mice were immunocompromised, they do contain subsets of immune
cells such as macrophages, which are known to be mainly responsible for nanoparticle removal from
circulation. The presence of a human tumor may be able to activate these macrophages, which in
turn may influence the circulation time of polymersomes. In this paper, we have therefore studied the
influence of tumor presence on the circulation time of polymersomes labeled with the gamma-emitting
radionuclide 111In through periodic blood sampling. Furthermore, the effect of the MPS on the
circulation time was examined through the administration of clodronate liposomes which are known
to cause macrophage depletion [29].
2. Materials and Methods
2.1. Chemicals
PBd-PEO (polybutadiene-polyethylene oxide) block copolymer with a Mw of 1900–900 g/mol
was purchased from Polymer Source (Dorval, QC, Canada). 111In was obtained from Covidien
(Petten, The Netherlands). The chlodronate liposomes were purchased from Liposoma B.V.
(Amsterdam, The Netherlands). The PD10 size exclusion columns were obtained from GE Healthcare
(Hoevelaken, The Netherlands). All other chemicals were purchased at Sigma Aldrich (Zwijndrecht,
The Netherlands).
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2.2. Polymersome Preparation
Polymersomes with an average diameter of 80 nm were prepared by the solvent displacement
method. Here, 1 mL PBS (phosphate-buffered saline) buffer solution containing 1 mM DTPA at pH
7.4 was added to a 20 mg/mL block copolymer solution in 1 mL acetone using a syringe pump under
magnetic stirring at 300 rpm. Subsequently, the acetone was evaporated using a rotavapor (Büchi,
Switzerland) under reduced pressure (100 mbar) for 15 min, and 1 mL PBS was added to bring the
final concentration to 10 mg/mL block copolymer. Before radiolabeling, remaining free DTPA was
removed from the solution by passing it through a 30 × 1 cm (length (L) × diameter (D)) Sephadex G
25 medium mesh size extrusion column equilibrated in PBS at a pH of 7.4.
2.3. Radiolabeling and Radionuclide Retention
Polymersomes were radiolabeled with 111In, where 20 µL tropolone was added to approximately
200 MBq of 111InCl3 in pH 2 HCl and 200 µL 10 mM HEPES. After an incubation time of 10 min,
1 mL polymersome solution, from which free DTPA was removed, was added and incubated for
30 min. Subsequently, the unencapsulated 111In was removed by passing the solution through a PD10
column, where 0.5 mL fractions were collected and those containing the polymersomes were used for
in vivo experiments.
To assess 111In retention in the vesicles, 500 µL of the 111In-containing polymersomes were
incubated with either 500 µL 1 mM DTPA or 500 µL BALB/c mouse serum for 24 h at 37 ◦C.
The polymersomes were separated from any free 111In-DTPA by passing them through a PD10 column,
or separated from the serum by passing them through a Sepharose 4B column (31 × 1 cm (L × D)) and
collecting 1 mL fractions.
2.4. Cryogenic Transmission Electron Microscopy (Cryo-TEM) and Dynamic Light Scattering (DLS)
Cryo-TEM images were obtained at an acceleration voltage of 120 keV using a Jeol JEM 1400
TEM (JEOL Ltd., Tokyo, Japan). The samples were prepared as follows: 4 µL 10 mg/mL polymersome
solution was deposited on a holey carbon film (Quantifoil 1.2/1.3, Cu 200 mesh grids) supported on
a TEM grid and blotted for four seconds. It was subsequently vitrified though rapid immersion in
liquid ethane (Leica EM GP version 16222032, Leica Microsystems B.V., Amsterdam, The Netherlands),
and then inserted into a cryo-holder (Gatan model 626, Gatan, Pleasanton, CA, USA).
DLS spectra were obtained by diluting the polymersome solution in PBS to a concentration of
0.01 mg/mL, after which it was placed in a toluene-filled, temperature-regulated bath (20 ◦C) in a DLS
apparatus. The DLS consisted of a JDS Uniphase 633 nm 35 mW laser, a fiber detector, an ALV sp
125 s/w 93 goniometer, and a Perkin Elmer photon counter (Perkin Elmer, Groningen, The Netherlands),
with an ALV-5000/epp correlator and software. The intensity autocorrelation function was determined
at 90◦, and the data was fitted using the Contin method [25].
2.5. Cellular Uptake Experiments
Fluorescent polymersome labeling was done using a fluorescent moiety attached to a lipophilic
tail with optimal excitation at 551 nm and emission at 567 nm (PKH26, Sigma-Aldrich) according to
manufacturer protocol. In short, 20 µL of polymersome solution (10 mg/mL) and 5 µL PKH26 dye
(working concentration of 2.5E-5 M) were diluted in provided Diluent C to 100 µL end volume and
incubated for 10 min. Excess PKH26 dye was removed using an Exosome Spin Column (Sigma-Aldrich)
according to manufacturer protocol. After solidifying and removing excess PBS, 100 µL of the
labeled polymersome solution was added to the column and centrifuged for 2 min at 750× g, leaving
only labeled polymersomes in Diluent C solution. The stock solution was diluted to 1 mL for
appropriate concentrations.
J774A.1 (mouse BALB/c monocyte macrophage) and MDA-MB-231 (human breast cancer) cells
were cultured in RPMI 1640 supplemented 1% penicillin/streptomycin and 5 or 10% fetal calf serum.
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All cells were incubated at 37 ◦C in a water-saturated atmosphere with 5% CO2. For uptake experiments,
cells were seeded on round coverslips of 18 mm in diameter and grown overnight. The cells were
incubated with 30 µL of labeled polymersome solution, diluted in 1 mL of culture media (6 µg/mL
of labeled polymersomes). Cells were washed with PBS and fixed with 4% para-formaldehyde
for 30 min at 30, 60, and 120 min after polymersome addition. Fixed cells were mounted on
tissue slides using Vectashield (VECTOR laboratories, Amsterdam, The Netherlands) with DAPI
(4′,6-diamidino-2-phenylindole) for nucleus staining.
Confocal microscopy (SP5, Leica, Amsterdam, The Netherlands) was used to capture at least
150 cells per time-point for both cell lines. With the use of FIJI software, the number of nuclei (threshold
and analyze particles function) and polymersomes (find maxima function) were counted in each image.
Dividing polymersome counts by nuclei counts, the concentration of polymersomes per nucleus
was determined.
2.6. Animals
The Dutch central committee on animal research and the local ethical committee on animal
research of the Radboud University approved this study under protocol 2015-0071 (2 September
2015). All animal experiments were performed according to the institutional guidelines. Upon arrival,
6–8-week-old female BALB/cAnNRj-Foxn1nu/Foxn1nu mice (Janvier Labs, Le Geneset-Saint-Isle, France)
were randomly tattooed for identification and were acclimatized for ≥4 days before any experimental
procedure. Mice had unlimited access to food and water and were maintained with 5–6 mice per cage
in a controlled environment (22 ± 1 ◦C, 55 ± 10% humidity, 12 h dark/light cycle). Cages were weekly
replaced by clean cages. Tumor-bearing mice were injected with 5 × 106 MDA-MB-231 breast cancer
cells in Matrigel, a model known for its leaky vasculature enabling the EPR effect [9], and tumors were
grown for three weeks. Just before the intravenous injections, the tumor length, width, and height
were measured with a caliper for tumor-bearing mice and tumor volume was calculated. Tumor size
was used to block-randomize the mice over the different groups.
2.7. Blood Clearance
To accurately quantify the circulation time of polymersomes in healthy and tumor-bearing mice,
two groups of mice (MDA-MB-231 tumor-bearing and non-tumor-bearing) were intravenously injected
with 200 µL, 1 MBq 111In radiolabeled 3 mg/mL polymersomes in PBS. Small blood samples were taken
of three randomly selected mice per group to measure the polymersome concentration at 1 min, 15 min,
30 min, 1 h, and 2 h postinjection. Four hours after injection, all animals were euthanized, and organs of
interest were collected and weighed. The radioactivity was counted in an Automated Wizard Gamma
Counter (Perkin Elmer). Three standard solutions of the 111In-polymersome solution were measured
to allow determination of the injected dose per gram of tissue (%ID/g). Paired two-sided Student’s
t-tests were used to compare the difference in organ uptake in healthy and tumor-bearing mice.
2.8. Clodronate Liposomes
To determine the effect of macrophages on polymersome circulation time, mice were injected
with clodronate liposomes to deplete all macrophages. Four different groups were defined, and two
groups (one with MDA-MB-231 tumors and one without tumors) were intravenously injected with
300 µL clodronate liposomes at 5 days and 24 h before the polymersome injection. The other two
groups (one with MDA-MB-231 tumors and one without tumors) received the polymersomes only.
After injection of the radiolabeled polymersomes (200 µL, 3 mg/mL polymersomes labeled with 1 MBq
111In), a small blood sample was collected at 30 min postinjection to measure activity of polymersomes
in blood. Four hours after injection, the animals were sacrificed followed by ex vivo biodistribution as
described previously. Tumors and parts of the liver and spleen were stored in formalin, and parts of
the liver and spleen were frozen in TissueTek (Sakura Finetek, Alphen aan den Rijn, The Netherlands)
in a tray containing isopentane on dry ice for immunohistochemistry.
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2.9. Immunohistochemistry
Spleen and livers were fixed overnight in 4% formalin in PBS and embedded in paraffin using
routine procedures. Then, 5 µm sections were deparaffinised with xylene, incubated in 3% H2O2 in
methanol for 20 min to block endogenous peroxidase, and subsequently rehydrated using a descending
ethanol series. Sections were incubated in 10 mM citrate buffer (pH 6.0) at 37 ◦C for 2 h and subsequently
incubated in 0.075% trypsin (Sigma-Aldrich) in PBS at 37 ◦C for 7 min. Nonspecific binding was
blocked by incubating the sections in 10% normal rabbit serum in PBS for 20 min and subsequently
the sections were incubated overnight at 4 ◦C with an anti F4/80 antibody 1:1000 in PBS, 2% NRbS
(Rat anti ms, hu F4/80;BM8 eBioscience). After washing with PBS, the sections were incubated for
30 min at RT with 200 times diluted biotinylated rabbit-anti-rat (Vector laboratories, cat.nr. BA-4001).
Finally, an avidin–biotin complex was applied to the sections for 30 min, and they were subsequently
incubated with Bright DAB (3,3′-diaminobenzidine) for 8 min at RT. Nuclei were stained by incubating
the sections for 5 s with hematoxylin and a subsequent wash with tap water for 10 min. Finally,
the sections were dehydrated with, consecutively, water, 50%, 70%, and twice 100% ethanol, and twice
with xylene, after which they were mounted with Permount, dried, and imaged.
3. Results and Discussion
3.1. Circulation Time in Healthy Versus Tumor-Bearing Mice
When employing nanoparticles like polymersomes for tumor theranostics, the EPR effect is
frequently used. Essential for sufficient tumor uptake through this form of passive targeting are
nanoparticle size (<200 nm) and long circulation times (~24 h) [30]. Previous research by our group
using Ncr nude mice bearing a U87 MG glioblastoma tumor indicated that the PBd-PEO polymersomes
circulate for a relatively short time [21]. However, the circulation time was not quantitatively
determined. SPECT images suggested polymersomes were completely cleared from circulation in
tumor-bearing mice, while they still circulated in healthy mice at 1 h p.i. Here, we quantitatively
investigated the circulation half-life of these 80 nm diameter polymersomes and determined the effect
of tumor presence on nanoparticle circulation.
Figure 1 shows the characterization of the polymersomes used in these studies with DLS and
Cryo-TEM. The radionuclide 111In was successfully encapsulated into the polymersomes with an
efficiency of 94 ± 2%. The stability of the encapsulated 111In was determined by challenging the
vesicles with either 1 mM DTPA at RT or mouse serum for 24 h at 37 ◦C. They displayed an 111In
retention of 98.5 ± 0.9%. When incubated with BALB/c mouse serum, less than 1% of the 111In
activity was associated with the serum fraction. Previous research by our group has established that
the polymersomes themselves are not cytotoxic [31]. These polymersome formulations have thus
proven stable enough to allow for further in vivo experiments. We were able to accurately determine
circulation half-lives by taking blood samples at a number of time intervals as evident from Figure 2.
The activity levels have been decay-corrected and subsequently fitted with A(t) = A0e
−t ln 2
t1/2 to
determine the circulation half-life. Here, t1/2 is the circulation half-life, t is the time in minutes, A(t) the
activity in the blood at time t, and A0 the initial 111In activity. The circulation half-life has been fitted
to be 117 min (R2 = 0.95) for healthy mice, and 5 min (R2 = 0.98) in tumor-bearing mice, which is a
surprisingly large difference. For this experiment, the mice have been randomly placed in the different
groups. Apart from the injection of the tumor cells in Matrigel in the tumor-bearing mice, the groups of
mice were identical and received identical treatment, which indicates that the difference in circulation
time stems from the tumor presence in the tumor-bearing mice. This dependence of the circulation time
on tumor presence is not very well known as, to the best of our knowledge, only one other group has
reported on this difference [22]. They observed an increase in M2-like macrophages in tumor-bearing
mice as compared to healthy ones, and found that tumor presence drastically impacted the circulation
time of their hydrogel nanoparticles while small molecules did not exhibit a difference in circulation
time. Tumor presence has been shown to cause a shift in the normal immune system balance from Th1
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to Th2 cytokines [32], which induce macrophages to differentiate into M-1 or M2-type macrophages,
respectively [22]. Jones et al. found a remarkably large difference in nanoparticle clearance rate
between the two macrophage types, where M2 macrophages result in much more rapid nanoparticle
clearance [33].
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Kai et al., who have studied the interaction of PEGylated PRINT (Particle Replication in Nonwetting
Templates) hydrogel nanoparticles with immune cells in different organs, have shown an increase in
bone marrow myelopoiesis in the presence of a tumor, and also found significantly higher liver uptake
in tumor-bearing mice, though no large differences in uptake were found in the spleen. The difference
in liver uptake was found to be associated mainly with a larger proportion of M2 macrophages, again
due to the tumor presence [22]. These macrophages could also be responsible for the increase in liver
uptake in the tumor-bearing mice in our study. There is, to the best of our knowledge, no indication
in the literature why splenic uptake of nanoparticles should decrease upon the presence of a tumor.
However, it could potentially be due to the enhanced rapid uptake of polymersomes in the liver,
resulting in less time for the spleen to take up the polymersomes. This, in turn, can be linked to the
significantly slower bl od flow n the liver as compared to the systemic ircul tion, giving the l ver
mac ophages, which are enhan ed due to the tumor presence, r latively e time to accumulate
nanopar cl s [37]. Hence, we have further investigated the involv ment of macrophages on the rapid
clear nce of nan particles.
3.2. Influence of Macrophages on Circulation Time
3.2.1. Cell Experiments
A short in vitro essay was set up to co par tes of macrophages and tumor cells.
Polymersomes wer incubated for a certain a it either MDA-MB-231 tumor cells or
J774 BALB/c mouse macrophage cells. In Figure 4, t e ta e rates are shown for the two individual
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cell lines. It is clear that macrophages not only take up the nanocarriers more quickly than the
tumor cells do, but they also take up more of the polymersomes within the first 120 min. With the
macrophages being present in large organs like the liver and spleen with a high blood throughput,
injected polymersomes will be efficiently filtered from the blood. Removal of the macrophages would
thus be expected to significantly increase circulation time in vivo.
Pharmaceutics 2019, 11, x 8 of 14 
 
cel  lines.  is clear that macrophages not only take up the nanocarrie s more quickly than e tumor 
cells do, but they also take up more of the polymersomes within the fi  120 min. With the 
macrophages being present in large organs like the liver and spl en with a high bl od throughput, 
injected polymersomes will b  eff ciently filt red from the blood. Removal of the macrophages would 
thus b  expected to significantly increase circulation time in ivo. 
 
Figure 4. Uptake of polymersomes in a J774 macrophage cell line vs the MDA-MB-231 tumor cells. 
Cells were incubated with 6 µg of polymersome solution and were fixed at 30, 60, and 120 min 
postaddition of polymersomes. The amount of polymersomes per cell nuclei was determined using 
FIJI (N > 150 cells per condition). Error bars represent the standard deviation. 
3.2.2. Animal Experiments 
The mice used in these studies were BALB/cAnNRj-Foxn1nu/nu nude mice. These animals are 
known for their immunodeficiency, which makes it easy to grow human tumors. However, despite 
their immunodeficiency, they do still have some macrophages, and there is a marked difference in 
clearance rate of the polymersomes in tumor-bearing versus non-tumor-bearing mice. To determine 
whether the rapid polymersome clearance was mediated by macrophages, clodronate liposomes 
were injected in the animals 5 days and 1 day prior to polymersome injection. Clodronate liposomes 
are known for their toxicity to macrophages, and the administration schedule should ensure complete 
macrophage ablation at time of polymersome injection [38]. To validate whether the macrophages 
were indeed destroyed by the clodronate liposomes, both the spleen and the liver were stained for 
the F4/80 antigen to study the presence of macrophages. In Figure 5, representative tissue sections of 
liver and spleen tissues of the four different treatment groups can be observed. While the stains 
indicate F4/80 presence in the control animals (brown), the animals pretreated with clodronate 
liposomes clearly do not contain any macrophages in their liver and spleen. 
To determine whether the macrophages were the main cause for the difference in circulation 
time between healthy and tumor-bearing mice, a blood sample was taken from the animals at 30 min 
post polymersome injection, and the activity in the blood was again measured at 4 h p.i. upon sacrifice 
of the animals (Figure 6). The amount of activity in the blood for the four different treatment groups 
correlates very strongly with the presence or absence of macrophages. The circulation time of 
polymersomes in tumor-bearing mice which had not undergone the chlodronate liposome treatment 
was significantly shorter than that in the other treatment groups (p < 0.005). There is no significant 
difference in circulation time between healthy animals, and the healthy and tumor-bearing mice 
which were pretreated with clodronate liposomes (t = 2.2, d.f. = 5, p = 0.08, and t = 1.1, d.f. = 4, p = 0.3 
at 4 h p.i., respectively, with t the t-value, d.f. the degrees of freedom, and p the probability). On the 
other hand, in tumor-bearing mice with macrophages, polymersomes are still rapidly removed from 
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3.2.2. Animal Experiments
The mice used in these studies were BALB/cAnNRj-Foxn1nu/nu nude mice. These animals are
known for their immu odeficiency, which makes it easy to grow human tumors. However, despite
their immunodeficiency, they do still have some macrophages, and there is a marked diff ence in
clearance rate f the polymersomes in tumor-bearing versus non-tumor-bearing ice. To determine
wh ther the rapid polymersome cleara ce was m diated by macrophages, clodronate lipos m s were
injected in t e animals 5 days and 1 day prior to polymersome injecti n. Clodronate liposome are
known for their toxicity to macrophages, and the administration schedule should ensure complete
macrophage ablation at t me of polymersome injection [38]. To validate whether t e macrophages were
indeed destroyed by the clodronate liposomes, both the spleen and the liver er stained for the F4/80
antig n to study the presence of mac phages. In Figure 5, repre entative tissu sections of liver and
spleen tissues of the four different tr atment grou s can be observ d. While the stains indicate F4/80
pres nce in the con rol animals (br wn), th a imals pr treated with clodronat liposomes clearly do
not contain any macrophages in their liver and spleen.
T d termine whether the m crophages wer the main cause for th difference in circulation
time betwe n healthy and tumor-be ring mic , a blood sa ple w s taken from th a imals at 30 min
post polym rsome injection, and the activity in the blood was gain measured at 4 h p.i. upon
sacrifice of the animals (Figure 6). The amount of activity in the blood for the four different treatment
groups correl tes very strongly with the presence or absence of macrophages. Th circulation ime of
polymersomes in tumor-bear ng mice which had not u d rgone the chlodronate liposome trea ent
was significantly shorter than that in the other treatment groups (p < 0.005). Th re is no significant
difference in irculation ime between healthy animals, and he healthy and tumor-b aring mice which
were pretr ated with cl dronate liposomes (t = 2.2, d.f. = 5, p = 0.08, nd t = 1.1, d.f. = 4, p = 0.3 at
4 h p.i., respectively, with t the t-value, d.f. the d grees of freedom, and p the probability). On the
other and, in tumor-bearing mice with macrop ages, polymersomes are still rapidly removed from
Pharmaceutics 2019, 11, 241 9 of 14
circulation. This implies that tumor presence indeed activates macrophages in the mice, causing the
nanoparticles to be removed rapidly from the blood circulation.
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Figure 6 shows the biodistribution data at 4 h p.i. for all treatment groups. Next to the activity
present in the blood, other significant differences in organ uptake can be found in the lungs, spleen,
and liver. While bone marrow uptake appears to be significantly increased in the tumor-bearing mice
which received the clodronate liposome treatment, it has to be noted that in these animals, there was
hardly any bone marrow present, so the very low bone marrow mass potentially inflated the measured
%ID/g value. Pretreatment with clodronate liposomes (and hence absence of macrophages) causes a
decrease in liver uptake, and increase in spleen and lung uptake. This appears to be mainly an effect
of the clodronate liposome distribution and subsequent macrophage depletion rather than of the
polymersomes themselves. While about 80–90% of the body macrophage population are located in
the liver [39], even in the control animals whose macrophages were not depleted, polymersomes are
preferentially taken up in the spleen (Figure 7). Liver macrophages (Kupffer cells) are eliminated
more completely at a much lower clodronate liposome concentration than macrophages in the spleen
(0.02 mL vs 0.1 mL per 10 g body weight, respectively) [40]. While several subpopulations of splenic
macrophages (the red pulp macrophages (RPM), marginal zone macrophages (MZM), and marginal
metallophilic macrophages) are depleted after the clodronate liposome injections [40,41], white pulp
macrophages (WPM) and tangible body macrophages in the spleen are affected but not depleted [42].
Nanoparticles have been shown by Demoy et al. to be predominantly captured by the MZM in mice
(96% [43]), but slightly more in the WPM than the RPM [44]. The WPM do not express the F4/80
antigen [45], which could explain why, despite the absence of visible macrophages in the F4/80 stained
spleens of the mice pretreated with clodronate liposomes (Figure 5), the uptake of the polymersomes
in the spleen of these animals is enhanced.
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(with and without tumor) were injected with 200 uL of the clodronate liposome solution at 5 days and 1
day prior to polymersome injection. The biodistribution was performed 4 h p.i. Bars represent mean
with SD.
Lung macrophages are not targeted at all through intravenous injection of the clodronate
liposomes [40] (they require intratracheal administrati n), resulting in the increased lung uptake upon
depletion of liver and spleen macrophages. Hence, it follows q i e logically that when the immun
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cells of the liver and part of the spleen are depleted, polymersome uptake increases in both the lungs
and spleen.
In the end, for efficient tumor targeting, longer circulation half-lives are required than even
the 2.3 h in the present study. As can be observed in Figure 7, there was no significant increase in
polymersome accumulation at the tumor site for the tumor-bearing mice which had been pretreated
with clodronate liposomes. Despite the significantly longer blood circulation time of the polymersomes
in the pretreated group, it is still insufficient for therapeutically significant tumor accumulation. Where
the circulation half-life of these polymersomes is in the order of two hours, liposomes are generally
still in circulation after 24 h, at which they can achieve a tumor accumulation of about 5% ID/g in the
MDA-MB-231 tumor model [7,46]. As it takes a longer time for the liposomes to be taken up by the
macrophages, their concentration in the blood is initially much larger resulting in the larger fraction
to accumulate at the tumor site. Furthermore, it is well established that uptake of nanovesicles via
the EPR effect takes time and that it takes several days to reach maximal tumor uptake [47,48]. The
lower circulation time of our polymersomes compared to liposomes is likely largely influenced by the
degree of PEGylation, as most research indicates that the typical PEG length necessary for nanocarriers
to achieve a stealth-like character corresponds to a molecular weight of about 2000, a factor 2 times
higher than the PEG length of the block copolymers used in this study [49,50]. Indeed, with a longer
PEG, PBd-PEO polymersomes have been found to circulate longer in healthy mice (15.8 h and 28.0 h
for 1100 g/mol and 2150 g/mol PEG, respectively) [26]. The minimal PEG length requirement is likely
because at lower molecular weights, the PEG is no longer flexible enough to prevent opsonization [34].
3.2.3. Comparison to Other Nanoparticle Systems
This study has focused on the circulation time of polymersomes in mice with one type of tumor.
However, the results obtained can be widely applied to a number of nanoparticle systems. Despite
only one other study having directly studied the circulation time effect of a tumor presence [22],
the results they obtained with their system closely match ours. They considered the influence of three
different tumor types, which all demonstrated shorter circulation times. This, together with the two
tumor models [21] studied by our group, lead us to believe this is a universal phenomenon. Despite
there not being any studies on liposome circulation time directly studying the influence of tumor
burden, Gabizon et al. have studied the biodistribution of a number of liposome compositions [51].
While using the same liposomes in their study, they unfortunately switched mouse type from Swiss
Webster female mice to BALB/c female mice when going from assessing circulation time in healthy vs
tumor-bearing mice, making it difficult to prove the effect of the tumor burden. Their data, however,
shows that about 20% ID is present in the blood after 25 h for the healthy mice vs less than 10% ID in
the tumor-bearing mice, suggesting that the effect of the tumor presence has a significant effect on
circulation time here as well. While more research is definitely required to draw definite conclusions,
the tumor influence on circulation time of nanoparticles appears to be a universal phenomenon, at least
in mice. However, as it is mainly the spleen which is responsible for filtering the polymersomes from
the blood circulation, one has to keep in mind that the results obtained in this study cannot directly
be translated to humans. Given that the spleen greatly varies between species, where the spleen of
mice is nonsinusoidal, and that of humans (and rats) is sinusoidal, translational studies are essential
to determine the extent of this phenomenon [39]. Clearly, though, it is not sufficient to study the
circulation behavior of nanoparticles solely in healthy mice. The large discrepancies in circulation time
between the healthy and tumor-bearing mice in this study have shown the need for proper assessment
of any nanoparticles designed for tumor targeting. A detailed understanding of the tumor activation
of the immune system and its subsequent effect on nanoparticle circulation time could very well prove
to be essential for the successful translation of any type of nanoparticle system to clinical applications.
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4. Conclusions
In this work, we have studied the influence of tumor presence on the circulation time of polymeric
nanocarriers upon intravenous injection. A large difference in circulation time has been observed
between healthy and tumor-bearing mice, with circulation half-lives of 117 min (R2 = 0.95) and 5 min
(R2 = 0.98), respectively. Cell studies have shown an increased uptake rate of the polymersomes in
macrophages vs tumor cell cultures. Through the administration of clodronate liposomes before the
intravenous polymersome injection, we have been able to deplete both spleen and liver of macrophages.
Subsequent circulation time studies have shown that the removal of macrophages in the liver and
spleen allowed the polymersomes in tumor-bearing mice to circulate equally long as in healthy mice,
pointing to macrophage activation as the main reason for the observed difference in circulation time.
The findings in this study greatly emphasize the need for evaluation of novel nanoparticle therapeutic
agents in mice with and without tumor, as the results in healthy animals cannot directly be translated
to circulation half-lives in tumor-bearing animals.
Author Contributions: Conceptualization, R.M.d.K., S.H., A.G.D.; Methodology, R.M.d.K., R.R., S.H.;
Formal analysis, R.M.d.K., R.R.; Investigation, R.M.d.K., R.R., A.K., J.M.-K., S.J.R.; Data curation, R.M.d.K.;
Writing—original draft preparation, R.M.d.K.; Writing—review and editing, R.M.d.K., R.R., A.K., J.M.-K., S.J.R.,
S.H., A.G.D.; Supervision, S.H., J.E., A.G.D.
Funding: The present study was funded by the SK foundation, the Zabawas foundation, and a ZonMw Early
Career Scientist Hotel grant, project nr. 43500401I.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Zhang, L.; Gu, F.; Chan, J.; Wang, A.; Langer, R.; Farokhzad, O. Nanoparticles in medicine: Therapeutic
applications and developments. Clin. Pharmacol. Ther. 2008, 83, 761–769. [CrossRef]
2. Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 2016, 1, 10–29. [CrossRef]
3. O’Brien, M.E.R.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D.G.;
Tomczak, P.; Ackland, S.P.; et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of
pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line
treatment of metastatic breast cancer. Ann. Oncol. 2004, 15, 440–449. [CrossRef]
4. Emerich, D.F.; Thanos, C.G. Targeted nanoparticle-based drug delivery and diagnosis. J. Drug Target. 2007,
15, 163–183. [CrossRef]
5. Hashizume, H.; Baluk, P.; Morikawa, S.; McLean, J.W.; Thurston, G.; Roberge, S.; Jain, R.K.; McDonald, D.M.
Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156,
1363–1380. [CrossRef]
6. Cheng, Z.; Al Zaki, A.; Hui, J.Z.; Muzykantov, V.R.; Tsourkas, A. Multifunctional nanoparticles: Cost versus
benefit of adding targeting and imaging capabilities. Science 2012, 338, 903–910. [CrossRef] [PubMed]
7. Bolkestein, M.; de Blois, E.; Koelewijn, S.J.; Eggermont, A.M.M.; Grosveld, F.; de Jong, M.; Koning, G.A.
Investigation of factors determining the enhanced permeability and retention effect in subcutaneous
xenografts. J. Nucl. Med. 2016, 57, 601–607. [CrossRef]
8. Shenoy, D.B.; Amiji, M.M. Poly(ethylene oxide)-modified poly(e-caprolactone) nanoparticles for targeted
delivery of tamoxifen in breast cancer. Int. J. Pharm. 2005, 293, 261–270. [CrossRef]
9. Ahmed, F.; Pakunlu, R.I.; Brannan, A.; Bates, F.; Minko, T.; Discher, D.E. Biodegradable polymersomes loaded
with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to
accumulated drug. J. Control. Release 2006, 116, 150–158. [CrossRef] [PubMed]
10. Charrois, G.J.R.; Allen, T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic
activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim.
Biophys. Acta-Biomembr. 2004, 1663, 167–177. [CrossRef] [PubMed]
11. Sawant, R.R.; Torchilin, V.P. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and
in vivo. Int. J. Pharm. 2009, 374, 114–118. [CrossRef]
12. Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of
polymeric nanoparticles. Mol. Pharm. 2008, 5, 505–515. [CrossRef] [PubMed]
Pharmaceutics 2019, 11, 241 13 of 14
13. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev.
2012, 64, 24–36. [CrossRef]
14. Li, S.-D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008, 5, 496–504.
[CrossRef] [PubMed]
15. Lasic, D.D.; Needham, D. The “Stealth” liposome: A prototypical biomaterial. Chem. Rev. 1995, 95, 2601–2628.
[CrossRef]
16. Yoo, J.-W.; Chambers, E.; Mitragotri, S. Factors that control the circulation time of nanoparticles in blood:
Challenges, solutions and future prospects. Curr. Pharm. Des. 2010, 16, 2298–2307. [CrossRef]
17. Lu, W.-L.; Qi, X.-R.; Zhang, Q.; Li, R.-Y.; Wang, G.-L.; Zhang, R.-J.; Wei, S.-L. A PEGylated liposomal platform:
Pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J. Pharmacol.
Sci. 2004, 95, 381–389. [CrossRef] [PubMed]
18. Klibanov, A.L.; Maruyama, K.; Torchilin, V.P.; Huang, L. Amphipathic polyethyleneglycols effectively prolong
the circulation time of liposomes. FEBS Lett. 1990, 268, 235–237. [CrossRef]
19. Litzinger, D.C.; Buiting, A.M.J.; van Rooijen, N.; Huang, L. Effect of liposome size on the circulation time
and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys.
Acta-Biomembr. 1994, 1190, 99–107. [CrossRef]
20. Brinkhuis, R.P.; Stojanov, K.; Laverman, P.; Eilander, J.; Zuhorn, I.S.; Rutjes, F.P.; Van Hest, J.C. Size dependent
biodistribution and SPECT imaging of 111In-labeled polymersomes. Bioconjug. Chem. 2012, 23, 958–965.
[CrossRef]
21. Wang, G.; de Kruijff, R.M.; Abou, D.; Ramos, N.; Mendes, E.; Franken, L.E.; Wolterbeek, H.T.;
Denkova, A.G. Pharmacokinetics of polymersomes composed of poly(butadiene-ethylene oxide); Healthy
versus tumor-bearing mice. J. Biomed. Nanotechnol. 2016, 12, 320–328. [CrossRef]
22. Kai, M.P.; Brighton, H.E.; Fromen, C.A.; Shen, T.W.; Luft, J.C.; Luft, Y.E.; Keeler, A.W.; Robbins, G.R.;
Ting, J.P.Y.; Zamboni, W.C.; et al. Tumor presence induces global immune changes and enhances nanoparticle
clearance. ACS Nano 2016, 10, 861–870. [CrossRef]
23. Wang, G.; de Kruijff, R.M.; Rol, A.; Thijssen, L.; Mendes, E.; Morgenstern, A.; Bruchertseifer, F.; Stuart, M.C.A.;
Wolterbeek, H.T.; Denkova, A.G. Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles.
Appl. Radiat. Isot. 2014, 85, 45–53. [CrossRef]
24. de Kruijff, R.M.; Drost, K.; Thijssen, L.; Morgenstern, A.; Bruchertseifer, F.; Lathouwers, D.; Wolterbeek, H.T.;
Denkova, A.G. Improved 225Ac daughter retention in InPO4 containing polymersomes. Appl. Radiat. Isot.
2017, 128, 183–189. [CrossRef]
25. Wang, G.; de Kruijff, R.M.; Stuart, M.C.A.; Mendes, E.; Wolterbeek, H.T.; Denkova, A.G. Polymersomes as
radionuclide carriers loaded via active ion transport through the hydrophobic bilayer. Soft Matter 2013, 9,
727–734. [CrossRef]
26. Photos, P.J.; Bacakova, L.; Discher, B.; Bates, F.S.; Discher, D.E. Polymer vesicles in vivo: Correlations with
PEG molecular weight. J. Control. Release 2003, 90, 323–334. [CrossRef]
27. Rideau, E.; Dimova, R.; Schwille, P.; Wurm, F.R.; Landfester, K. Liposomes and polymersomes: A comparative
review towards cell mimicking. Chem. Soc. Rev. 2018, 47, 8571–8610. [CrossRef] [PubMed]
28. Discher, B.M.; Won, Y.-Y.; Ege, D.S.; Lee, J.C.-M.; Bates, F.S.; Discher, D.E.; Hammer, D.A. Polymersomes:
Tough vesicles made from diblock copolymers. Science 1999, 284, 1143–1146. [CrossRef] [PubMed]
29. Zeisberger, S.M.; Odermatt, B.; Marty, C.; Zehnder-Fjällman, A.H.M.; Ballmer-Hofer, K.; Schwendener, R.A.
Clodronate-liposome-mediated depletion of tumor-associated macrophages: A new and highly effective
antiangiogenic therapy approach. Br. J. Cancer 2006, 95, 272–281. [CrossRef]
30. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in
macromolecular therapeutics: A review. J. Control. Release 2000, 65, 271–284. [CrossRef]
31. de Kruijff, R.M.; van der Meer, A.J.G.M.; Windmeijer, C.A.A.; Kouwenberg, J.J.M.; Morgenstern, A.;
Bruchertseifer, F.; Sminia, P.; Denkova, A.G. The therapeutic potential of polymersomes loaded with 225Ac
evaluated in 2D and 3D in vitro glioma models. Eur. J. Pharm. Biopharm. 2018, 127, 85–91. [CrossRef]
32. Kiessling, R.; Wasserman, K.; Horiguchi, S.; Kono, K.; Sjoè Berg, J.; Pisa, P.; Petersson, M. Tumor-induced
immune dysfunction. Cancer Immunol. Immunother. 1999, 48, 353–362. [CrossRef] [PubMed]
33. Jones, S.W.; Roberts, R.A.; Robbins, G.R.; Perry, J.L.; Kai, M.P.; Chen, K.; Bo, T.; Napier, M.E.; Ting, J.P.Y.;
DeSimone, J.M.; et al. Nanoparticle clearance is governed by Th1/Th2 immunity and strain background.
J. Clin. Invest. 2013, 123, 3061–3073. [CrossRef] [PubMed]
Pharmaceutics 2019, 11, 241 14 of 14
34. Owens, D.E., III; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric
nanoparticles. Int. J. Pharm. 2006, 307, 93–102. [CrossRef]
35. Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Livaniou, E.; Evangelatos, G.; Ithakissios, D.S. Effect of
copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of
PLGA-mPEG nanoparticles. Int. J. Pharm. 2003, 259, 115–127. [CrossRef]
36. Porter, C.J.H.; Moghimi, S.M.; Illum, L.; Davis, S.S. The polyoxyethylene/polyoxypropylene block co-polymer
Poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of
rabbit bone marrow. FEBS Lett. 1992, 305, 62–66. [CrossRef]
37. Tsoi, K.M.; MacParland, S.A.; Ma, X.-Z.; Spetzler, V.N.; Echeverri, J.; Ouyang, B.; Fadel, S.M.; Sykes, E.A.;
Goldaracena, N.; Kaths, J.M.; et al. Mechanism of hard-nanomaterial clearance by the liver. Nat. Mater. 2016,
15, 1212–1221. [CrossRef]
38. Terry, S.Y.A.; Boerman, O.C.; Gerrits, D.; Franssen, G.M.; Metselaar, J.M.; Lehmann, S.; Oyen, W.J.G.;
Gerdes, C.A.; Abiraj, K. 111In-anti-F4/80-A3-1 antibody: A novel tracer to image macrophages. Eur. J. Nucl.
Med. Mol. Imaging 2015, 42, 1430–1438. [CrossRef] [PubMed]
39. Bertrand, N.; Leroux, J.-C. The journey of a drug-carrier in the body: An anatomo-physiological perspective.
J. Control. Release 2012, 161, 152–163. [CrossRef]
40. Van Rooijen, N.; Sanders, A. Liposome mediated depletion of macrophages: Mechanism of action, preparation
of liposomes and applications. J. Immunol. Methods 1994, 174, 83–93. [CrossRef]
41. Van Rooijen, N.; Bakker, J.; Sanders, A. Transient suppression of macrophage functions by liposome-encapsulated
drugs. Trends Biotechnol. 1997, 15, 178–185. [CrossRef]
42. Aichele, P.; Zinke, J.; Grode, L.; Schwendener, R.A.; Kaufmann, S.H.E.; Seiler, P. Macrophages of the splenic
marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of
specific T cell responses. J. Immunol. 2003, 171, 1148–1155. [CrossRef] [PubMed]
43. Demoy, M.; Gibaud, S.; Andreux, J.P.; Weingarten, C.; Gouritin, B.; Couvreur, P. Splenic trapping of
nanoparticles: Complementary approaches for in situ studies. Pharm. Res. 1997, 14, 463–468. [CrossRef]
44. Demoy, M.; Andreux, J.P.; Weingarten, C.; Gouritin, B.; Guilloux, V.; Couvreur, P. Splenic capture of
nanoparticles: Influence of animal species and surface characteristics. Pharm. Res. 1999, 16, 37–41. [CrossRef]
45. Gordon, S.; Pluddemann, A.; Martinez Estrada, F. Macrophage heterogeneity in tissues: Phenotypic diversity
and functions. Immunol. Rev. 2014, 262, 36–55. [CrossRef] [PubMed]
46. Dawidczyk, C.M.; Russell, L.M.; Hultz, M.; Searson, P.C. Tumor accumulation of liposomal doxorubicin in
three murine models: Optimizing delivery efficiency. Nanomedicine 2017, 13, 1637–1644. [CrossRef]
47. Wong, A.D.; Ye, M.; Ulmschneider, M.B.; Searson, P.C. Quantitative analysis of the enhanced permeation and
retention (EPR) effect. PLoS One 2015, 10, e0123461. [CrossRef]
48. Ngoune, R.; Peters, A.; von Elverfeldt, D.; Winkler, K.; Pütz, G. Accumulating nanoparticles by EPR: A route
of no return. J. Control. Release 2016, 238, 58–70. [CrossRef]
49. Gref, R.; Minamitake, Y.; Peracchia, M.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating
polymeric nanospheres. Science 1994, 263, 1600–1603. [CrossRef]
50. Peracchia, M.T. Stealth nanoparticles for intravenous administration. STP Pharma Sci. 2003, 13, 155–161.
51. Gabizon, A.; Papahadjopoulos, D. Liposome formulations with prolonged circulation time in blood and
enhanced uptake by tumors (phospholipid vesicles/drug delivery systems/cancer therapy/glycolipids.
Proc. Natl. Acad. Sci. USA 1988, 85, 6949–6953. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
